Clinical Trial COGADVL0912


PH 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Principal Investigator(s)

Scott Borinstein


  • Protocol No. COGADVL0912
  • Open Date: 04/05/2011
  • Staging: Phase I/II
  • Age Group: Children
  • Scope: National
  • Objective: 1.1.1 To estimate the maximum tolerated dose (MTD) and recommend a Phase 2 dose of PF-02341066 administered orally twice daily to children with relapsed/refractory solid tumors and anaplastic large cell lymphoma (ALCL). 1.1.2 To define and describe the toxicities of PF-02341066 administered on this schedule. 1.1.3 To characterize the pharmacokinetics of PF-02341066 in children with refractory cancer.
  • Disease Sites: Pediatrics; Pediatric Lymphoma; Neuroblastoma (Pediatrics)
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Crizotinib; PF-02341066
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00939770
  • Secondary Protocol No: ADVL0912



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.